Two Cells

About Two Cells

Established in April 2003 as a spin-out from Hiroshima University, TWO CELLS, Ltd. operates in the regenerative medicine sector. The company's inception was the culmination of a pre-venture project for the regenerative medicine of osteocartilaginous tissues, initiated by the Japan Science and Technology Agency (JST) from 2000 to 2003. The corporate logo, symbolizing two cells and infinity, represents the two founders and the limitless potential of their medical technologies. The firm is dedicated to the research, development, manufacturing, and marketing of regenerative medical products, with a focus on treatments utilizing Mesenchymal Stem Cells (MSCs).

TWO CELLS' core business revolves around developing treatments for conditions with unmet medical needs. The company has developed a proprietary cell culture method using serum-free media (STK series) that significantly increases the proliferation of MSCs while maintaining their crucial differentiation potentials. This technology addresses the challenge of securing a sufficient number of cells required for therapeutic applications. Its primary product pipeline includes gMSC®1, an allogeneic synovial mesenchymal stem cell-derived three-dimensional artificial tissue designed for treating traumatic cartilage injury and osteochondritis dissecans. This product utilizes several patented technologies, including the serum-free culture techniques and a formulation technology called “TEC” (Tissue-Engineered Construct), which creates a flexible, three-dimensional construct without artificial scaffolding materials.

The company's business model is an integrated "R-D-M System," covering research, development, and marketing. Revenue is generated through activities such as licensing agreements and future product sales. A notable partnership is the license agreement with KAKEN Pharmaceutical Co., Ltd. for gMSC®1. Under this agreement, TWO CELLS is responsible for clinical trials, manufacturing, and obtaining regulatory approval in Japan, while KAKEN will handle marketing post-approval. Upon the product's launch, TWO CELLS will receive royalties from KAKEN based on sales figures. The company has received support from various governmental bodies, including JST, the New Energy and Industrial Technology Development Organization (NEDO), the Ministry of Economy, Trade and Industry (METI), and the Japan Agency for Medical Research and Development (AMED).